Fixing a Hole: a retrospective cohort study evaluating HAV, HBV, tetanus screening, and vaccination during hospitalization in persons who use substances
- PMID: 38681966
- PMCID: PMC11055482
- DOI: 10.1177/20499361241245822
Fixing a Hole: a retrospective cohort study evaluating HAV, HBV, tetanus screening, and vaccination during hospitalization in persons who use substances
Abstract
Background: Rates of serious injection-related infections in persons who use drugs have increased. Resulting admissions are an opportunity for screening and vaccination of preventable infections such as hepatitis A virus (HAV), hepatitis B virus (HBV), and tetanus.
Design and methods: We conducted a retrospective review of adults with documented substance use admitted for bacterial infection between July 2015 and March 2020. We evaluated HAV, HBV, and tetanus vaccination status at admission, along with screening for HAV and HBV infection and immunity. We identified the proportion of patients at risk for infection who received HAV, HBV, and tetanus vaccines during admission and patient-level factors associated with vaccination.
Results: We identified 280 patients who met our inclusion criteria. Of the 198 (70.7%) patients at risk for HAV, infectious disease providers recommended vaccination for 21 (10.6%) and 15 (7.6%) received HAV vaccine. Of the 174 (62.1%) patients at risk for HBV, infectious disease providers recommended vaccination for 32 (18.3%) and 25 (14.4%) received HBV vaccine. A large proportion of patients (31.4%, 88) had no documentation of prior tetanus vaccination, and infectious disease providers recommended tetanus vaccination for three (1.1%) and five patients (1.8%) received a tetanus booster. Infectious disease consult vaccine recommendations were statistically significantly associated with HAV or HBV vaccination prior to discharge.
Conclusion: Over 70% of our population is at risk for one or more of these preventable infections. Efforts are needed to maximize inpatient screening and vaccination for HAV, HBV, and tetanus in patients with barriers to care.
Keywords: hepatitis A; hepatitis B; substance-related disorder; tetanus; vaccination.
© The Author(s), 2024.
Figures
Similar articles
-
Screening and vaccination rates for tetanus, hepatitis A, and hepatitis B among individuals with substance use disorders who are hospitalized in an integrated U.S. health system.Clin Infect Dis. 2025 May 20:ciaf251. doi: 10.1093/cid/ciaf251. Online ahead of print. Clin Infect Dis. 2025. PMID: 40392561
-
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.Vaccine. 2018 Jan 25;36(4):453-460. doi: 10.1016/j.vaccine.2017.12.018. Epub 2017 Dec 16. Vaccine. 2018. PMID: 29254840 Free PMC article.
-
Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.Am J Gastroenterol. 2008 Jan;103(1):138-46. doi: 10.1111/j.1572-0241.2007.01609.x. Epub 2007 Oct 26. Am J Gastroenterol. 2008. PMID: 17970833
-
Screening for hepatitis A and B antibodies in patients with chronic liver disease.Am J Med. 2005 Oct;118 Suppl 10A:28S-33S. doi: 10.1016/j.amjmed.2005.07.014. Am J Med. 2005. PMID: 16271538 Review.
-
Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.Expert Rev Vaccines. 2019 Sep;18(9):921-933. doi: 10.1080/14760584.2019.1646643. Epub 2019 Aug 1. Expert Rev Vaccines. 2019. PMID: 31328999
References
-
- Larney S, Peacock A, Mathers BM, et al.. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend 2017; 171: 39–49. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous